- Home
- SUJA vs ASMB Comparison
SUJA vs ASMB Comparison
Compare SUJA & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUJA | ASMB |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.8M | 512.1M |
| IPO Year | 2026 | 2010 |
Fundamental Metrics
Financial Performance| Metric | SUJA | ASMB |
|---|---|---|
| Price | $6.14 | $26.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.20 |
| AVG Volume (30 Days) | ★ 162.4K | 136.3K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.71 | $19.13 |
| 52 Week High | $11.93 | $39.71 |
Technical Indicators
Market Signals| Indicator | SUJA | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 31.68 | 52.53 |
| Support Level | N/A | $25.68 |
| Resistance Level | $11.04 | $30.36 |
| Average True Range (ATR) | 0.97 | 1.33 |
| MACD | -0.15 | 0.02 |
| Stochastic Oscillator | 1.62 | 55.62 |
Price Performance
Historical ComparisonAbout ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.